Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit
ANAPHYLASHOCK
1 other identifier
observational
339
1 country
2
Brief Summary
Anaphylaxis is a severe life-threatening reaction following exposure to an antigen. Its incidence is progressively increasing in the general population over years, accompanied with an increased number of hospitalizations. Although rare, this condition is often associated with a significant morbidity and mortality. The mortality rate has been recently estimated at 0.84 (95% CI, 0.79 to 0.88) per million per year in the French adult population. Age, chronic medication and cardiac or pulmonary comorbidities have been reported to increase the risk of a severe reaction. Obesity, age and cardiovascular comorbidities have been identified as risk factors for fatal anaphylaxis. However, the risk factors for death after ICU admission have not been elucidated yet.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2017
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2019
CompletedFirst Submitted
Initial submission to the registry
February 27, 2020
CompletedFirst Posted
Study publicly available on registry
March 2, 2020
CompletedMarch 11, 2020
February 1, 2020
2.5 years
February 27, 2020
March 9, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
In-ICU mortality
The number of participants deceased within ICU hospitalisation
Day 30
Secondary Outcomes (5)
Volume of fluid administered
Day 30
Amount of epinephrine
Day 30
Amount of norepinephrine
Day 30
Number and severity of organ failure
Day 30
Extracorporeal life support requirement
Day 30
Eligibility Criteria
All patients admitted to ICU following anaphylaxis
You may qualify if:
- Being \> 18 years old
- suffered an anaphylactic reaction, regardless of the location or causative allergen
- transferred alive in an ICU
You may not qualify if:
- dead within less than one hour after admission
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
University Hospital of Nancy
Nancy, 54511, France
University Hospital of Strasbourg
Strasbourg, France
Related Publications (1)
Guerci P, Tacquard C, Chenard L, Millard D, Soufir L, Malinovsky JM, Garot M, Lalot JM, Besch G, Louis G, Thion LA, Charpentier C, Kimmoun A, Danguy Des Deserts M, Carreira S, Plantefeve G, Novy E, Abraham P, Mertes PM; Societe Francaise d'Anesthesie et Reanimation (SFAR) Research Network. Epidemiology and outcome of patients admitted to intensive care after anaphylaxis in France: a retrospective multicentre study. Br J Anaesth. 2020 Dec;125(6):1025-1033. doi: 10.1016/j.bja.2020.08.024. Epub 2020 Sep 12.
PMID: 32928517DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 27, 2020
First Posted
March 2, 2020
Study Start
January 1, 2017
Primary Completion
June 30, 2019
Study Completion
December 31, 2019
Last Updated
March 11, 2020
Record last verified: 2020-02
Data Sharing
- IPD Sharing
- Will not share